CSL Vifor faces revenue slump after Tavneos loses European market access

CSL Vifor, the specialty pharmaceuticals unit of Australia's CSL Limited, is experiencing a notable decline in expected revenue following the removal of its drug Tavneos from the European market. The parent company indicated that Vifor's sales could drop by approximately 25% in the current fiscal period, attributing the shortfall to this regulatory setback.